09:02 AM EST - Lexston Life Sciences : Is pleased to announce that the Company’s wholly owned subsidiary, Egret Bioscience Ltd. has developed and validated a targeted genetic barcode consisting of eight Single Nucleotide Polymorphism for psychedelic mushroom genetic identification. Egret has previously developed and published similar genetic identification tests for the Cannabis Industry and have been offering this service to licensed producers through its affiliated licensed lab, Zenalytic Laboratories Ltd. Lexston Life Sciences
shares C.LEXT are trading unchanged at $0.10.
